Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib

被引：3
|
作者：
Loglisci, Giuseppina [1 ]
Breccia, Massimo [1 ]
Nanni, Mauro [1 ]
Mancini, Marco [1 ]
De Cuia, Rosa [1 ]
Cannella, Laura [1 ]
Salaroli, Adriano [1 ]
Federico, Vincenzo [1 ]
Serrao, Alessandra [1 ]
Loglisci, Maria Giovanna [1 ]
Santopietro, Michelina [1 ]
Alimena, Giuliana [1 ]
机构：
[1] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Rome, Italy
来源：
LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 07期
关键词：
BCR-ABL; GENE AMPLIFICATION; EXPRESSION; MESYLATE; THERAPY; ST1571; CELLS;
D O I：
10.3109/10428194.2011.565394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1372 / 1375
页数：4
相关论文
共 50 条
  • [31] Imatinib resistance in chronic myeloid leukemia due to a rare mutation
    Balasubramanian, Priyavadhana
    Chopra, Anita
    Verma, Deepak
    Singh, Indresh K.
    Kumar, Akash
    Sharma, Atul
    Kumar, Rajive
    LEUKEMIA & LYMPHOMA, 2017, 58 (07) : 1750 - 1752
  • [32] Chronic myeloid leukemia. Genetic mechanisms of resistance to Imatinib
    Bengio, Raquel M.
    Gargallo, Patricia
    Barreyro, Paula
    Bitton, Roberto
    Larripa, Irene
    MEDICINA-BUENOS AIRES, 2007, 67 : 71 - 74
  • [33] New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance
    Kantarjian, Hagop M.
    Talpaz, Moshe
    Giles, Francis
    O'Brien, Susan
    Cortes, Jorge
    ANNALS OF INTERNAL MEDICINE, 2006, 145 (12) : 913 - 923
  • [34] Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure
    Hochhaus, Andreas
    EXPERT OPINION ON PHARMACOTHERAPY, 2007, 8 (18) : 3257 - 3264
  • [35] Contribution of BCR-ABL kinase domain mutations to imatinib mesylate resistance in Philadelphia chromosome positive Malaysian chronic myeloid leukemia patients
    Elias, Marjanu Hikmah
    Baba, Abdul Aziz
    Husin, Azlan
    Abdullah, Abu Dzarr
    Hassan, Rosline
    Sim, Goh Ai
    Wahid, S. Fadilah Abdul
    Ankathil, Ravindran
    HEMATOLOGY REPORTS, 2012, 4 (04) : 86 - 90
  • [36] DASATINIB, HIGH-DOSE IMATINIB AND NILOTINIB IN CHINESE PATIENTS WITH CHRONIC PHASE OF CHRONIC MYELOID LEUKEMIA WITH IMATINIB-RESISTANCE OR -INTOLERANCE: AN ECONOMIC EVALUATION
    Wu, B.
    VALUE IN HEALTH, 2015, 18 (07) : A460 - A460
  • [37] Comparison of Dasatinib, Nilotinib, and Imatinib in the Treatment of Chronic Myeloid Leukemia
    Ciarcia, Roberto
    Damiano, Sara
    Puzio, Maria Valeria
    Montagnaro, Serena
    Pagnini, Francesco
    Pacilio, Carmen
    Caparrotti, Giuseppe
    Bellan, Cristiana
    Garofano, Tiziana
    Polito, Maria Sole
    Giordano, Antonio
    Florio, Salvatore
    JOURNAL OF CELLULAR PHYSIOLOGY, 2016, 231 (03) : 680 - 687
  • [38] PHILADELPHIA CHROMOSOME TRANSLOCATION AND CHRONIC MYELOID LEUKEMIA
    BORGAONKAR, DS
    LANCET, 1973, 1 (7814): : 1250 - 1250
  • [39] Imatinib: Chromosome Aberrations in Chronic Myeloid Leukemia
    不详
    MOLECULAR DIAGNOSIS & THERAPY, 2012, 16 (05) : 325 - 325
  • [40] Evolution of resistance to imatinib mesilate and multidrug resistance in accelerated phase of chronic myeloid leukemia
    Kruglov, S.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 455 - 456
12345